Filters close
access_time Embargo lifts in 2 days
Embargo will expire: 2-Apr-2024 11:00 AM EDT Released to reporters: 28-Mar-2024 4:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 2-Apr-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 28-Mar-2024 3:05 PM EDT
Study Shows Improved Outcomes in Hospitals Accredited for Rectal Cancer Surgery
American College of Surgeons (ACS)

Hospitals accredited by the American College of Surgeons (ACS) National Accreditation Program for Rectal Cancer (NAPRC) demonstrate significantly better outcomes for patients undergoing rectal cancer surgery compared to non-accredited hospitals, according to a new study published in the Journal of the American College of Surgeons (JACS).

Newswise: Cell Division Quality Control ‘Stopwatch’ Uncovered
27-Mar-2024 7:05 PM EDT
Cell Division Quality Control ‘Stopwatch’ Uncovered
University of California San Diego

UC San Diego biologists have uncovered a quality control timing mechanism tied to cell division. The “stopwatch” function keeps track of mitosis and acts as a protective measure when the process takes too long, preventing the formation of cancerous cells.

   
Released: 28-Mar-2024 12:05 PM EDT
Neoadjuvant Chemotherapy Proves Effective for Locally Advanced Penile Squamous Cell Carcinoma
Ochsner Health

In a recent multi-center study published in the Journal of the National Cancer Institute, researchers examined the effects of neoadjuvant chemotherapy (NAC) on patients suffering from locally advanced penile squamous cell carcinoma (PSCC).

access_time Embargo lifts in 2 days
Embargo will expire: 29-Mar-2024 11:00 AM EDT Released to reporters: 28-Mar-2024 12:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 29-Mar-2024 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Study flips treatment paradigm in bilateral Wilms tumor, shows resistance to chemotherapy may point toward favorable outcomes
Released: 28-Mar-2024 12:05 PM EDT
Study flips treatment paradigm in bilateral Wilms tumor, shows resistance to chemotherapy may point toward favorable outcomes
St. Jude Children's Research Hospital

St. Jude Children’s Research Hospital scientists studying bilateral Wilms tumor found that chemotherapy resistance correlates with tumors favorable to surgery, reducing the need for additional therapy.

Newswise: Study explores the future of at-home cancer treatment
Released: 28-Mar-2024 12:00 PM EDT
Study explores the future of at-home cancer treatment
Keck Medicine of USC

A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.

27-Mar-2024 3:05 PM EDT
Study provides a first look at oncologists' views on ethical implications of AI in cancer care
Dana-Farber Cancer Institute

In a survey of more than 200 U.S. oncologists, vast majority indicate that oncologists should be able to explain how AI works to their patients. Respondents say AI developers, more than oncologists or hospitals, have responsibility for legal issues arising from AI use in cancer care.

Newswise: Dual-miRNA Triggered DNA Nanomachine for Breast Cancer Subtype Detection and Treatment
Released: 28-Mar-2024 9:40 AM EDT
Dual-miRNA Triggered DNA Nanomachine for Breast Cancer Subtype Detection and Treatment
Chinese Academy of Sciences

The researchers developed an intelligent DNA-Au nanomachine triggered by two endogenous cancer metastasis-related miRNAs to serve as a theranostics nanoplatform for effective discrimination and targeted therapy of specific breast cancer cell types.

Released: 28-Mar-2024 9:35 AM EDT
Serum Detect Launches with Novel T-Cell Analysis Approach for Cancer Early Detection at AACR
Serum Detect Inc.

The new company, led by a former executive from Foundation Medicine and Gritstone bio, is using advances in T-cell receptor repertoire analysis to reveal previously undetectable signals in standard liquid biopsy samples.

Newswise: Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer
Released: 28-Mar-2024 9:00 AM EDT
Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer
Dana-Farber Cancer Institute

Andrew E. Place, MD, PhD, has been named as Vice President, Pediatric Chief Medical Officer (CMO) at Dana-Farber Cancer Institute (within the Department of Pediatric Oncology) and Boston Children’s Hospital (within the Division of Hematology/Oncology) for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Released: 28-Mar-2024 8:05 AM EDT
Aster Insights Announces AACR Schedule of ORIEN Presentations
Aster Insights

Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced its schedule of research presentations at the American Association for Cancer Research (AACR) annual meeting in San Diego, California, April 5-10, 2024.

Newswise: 1920_active-surveillance-cancer-cedars-sinai.jpg?10000
Released: 27-Mar-2024 3:05 PM EDT
RESEARCH ALERT: Malpractice Trends Involving Active Surveillance Across Cancers
Cedars-Sinai

In a new study, Cedars-Sinai Cancer investigators explored malpractice trends related to active surveillance as a treatment strategy across cancers. They found that to date, there has been no successful litigation related to active surveillance.

Newswise: Combining Epigenetic Cancer Medications May Have Benefit for Colorectal Cancers and Other Tumor Types
27-Mar-2024 1:30 PM EDT
Combining Epigenetic Cancer Medications May Have Benefit for Colorectal Cancers and Other Tumor Types
Van Andel Institute

A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances.

Released: 27-Mar-2024 1:05 PM EDT
HERSTORY: Democratizing cancer genetic testing to reduce healthcare disparities
University of California, Los Angeles (UCLA), Health Sciences

HERSTORY is focused on understanding genetic, environmental, socio-economic, and other determinants of cancer in women with a family history of the disease.

Newswise: Researchers turn back the clock on cancer cells to offer new treatment paradigm
Released: 27-Mar-2024 12:05 PM EDT
Researchers turn back the clock on cancer cells to offer new treatment paradigm
St. Jude Children's Research Hospital

St. Jude Children’s Research Hospital scientists reversed an aggressive cancer, reverting malignant cells towards a more normal state.

Newswise: Palliative care leader receives prestigious ASCO Special Award
Released: 27-Mar-2024 10:05 AM EDT
Palliative care leader receives prestigious ASCO Special Award
Dana-Farber Cancer Institute

The American Society of Clinical Oncology (ASCO) recognized Janet L. Abrahm, MD, FACP, FAAHPM, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, as a recipient of an ASCO Special Award, the Society’s highest honor.

Newswise: Experts Highlight Strategies for Cancer Control and Prevention
Released: 27-Mar-2024 9:05 AM EDT
Experts Highlight Strategies for Cancer Control and Prevention
Rutgers Cancer Institute of New Jersey

Many cancers can be prevented, and others can be detected early in their development, treated and cured.

Newswise: Empowering Minority Cancer Patients: Tips for Advocacy and Support
Released: 27-Mar-2024 9:05 AM EDT
Empowering Minority Cancer Patients: Tips for Advocacy and Support
Rutgers Cancer Institute of New Jersey

Mariam F. Eskander, MD, MPH, surgical oncologist in the Gastrointestinal Oncology Program at Rutgers Institute of New Jersey, offers insight and tips for minority individuals navigating a cancer diagnosis and how we can all work together to mitigate cancer disparities.

Newswise: Testicular Cancer: Expert Advice for Early Detection
Released: 27-Mar-2024 9:05 AM EDT
Testicular Cancer: Expert Advice for Early Detection
Rutgers Cancer Institute of New Jersey

Vignesh T. Packiam, MD, director of Clinical and Translational Research in Urologic Oncology and a urologic oncologist in the Urologic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center, shares about testicular cancer and what men should know.


Showing results

120 of 24573

close
4.38691